Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutated ERBB4: a novel drug target in metastatic melanoma?

Pigment cell & melanoma research - 1 Dec 2009

Kurppa Kari, Elenius Klaus

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to ErbB Receptors
Share to ERBB4 gene
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Metastasis

Share to Receptor, ErbB-4

Share to Skin Neoplasms

Source

Identifiers

PMID: 19735458
DOI: 10.1111/j.1755-148X.2009.00635.x

Genes

ERBB4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated ERBB4: a novel drug target in metastatic melanoma?PMID 19735458Read ↗

A growing family: adding mutated Erbb4 as a novel cancer target.Semantic proximity Read ↗

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant MelanomaSemantic proximity Read ↗

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.Semantic proximity Read ↗

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.Semantic proximity Read ↗

New drug targets in metastatic melanoma.Semantic proximity Read ↗

Molecular therapy for melanoma: useful and not useful targets.Semantic proximity Read ↗

Targeting NRAS Mutations in Advanced Melanoma.Semantic proximity Read ↗

Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.Semantic proximity Read ↗

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsSemantic proximity Read ↗

NRAS-mutant melanoma: response to chemotherapy.Semantic proximity Read ↗

ErbB-targeted therapeutic approaches in human cancerSemantic proximity Read ↗

Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.